anti-gp 100:154 tcell receptor peripheral blood lymphocyte
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00923195)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanocyte protein PMELImmunity, passive
PMEL immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-gp 100:154 tcell receptor peripheral blood lymphocyte
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00923195 | Phase 2 | Dec 1, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2008 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1